Janeczko Małgorzata, Niedzielska Ewa, Pietras Wojciech
Department and Clinic of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
Adv Clin Exp Med. 2015 May-Jun;24(3):497-504. doi: 10.17219/acem/43768.
Wilms' tumor is the most common kidney cancer in children. Treatment consists of pre- and post-operative chemotherapy, surgery and in some cases radiotherapy. The treatment of nephroblastomas is very effective. Hence, the population of adult patients cured of this cancer in their childhood is steadily growing, generating a need for long-term health assessment, including renal function, due to the specifications of the therapy and the location of the tumor.
The aim of the study was to evaluate nephrological complications after treatment for nephroblastoma.
The study group consisted of 50 children treated in the Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation at Wroclaw Medical University (Poland) from 2002 to 2012. An analysis of the patients' medical histories was carried out. The glomerular filtration rate estimated by the Schwartz formula (GFR by Schwartz), serum creatinine levels, urea and electrolyte concentrations; the results of urinalysis and blood pressure were assessed. Each of these analyses was performed at the time of diagnosis, at the end of therapy, as well as 6 months, one year and two years after its completion.
The study showed that, in most cases, implemented therapy had no significant impact on the deterioration of renal parameters in the two-year period following treatment for Wilms' tumor. However, the group of patients treated with cyclophosphamide and carboplatin required more careful monitoring, due to a higher risk of renal function deterioration.
The study shows that the problem of nephrotoxicity after treatment for Wilms' tumor is more frequent than indicated in other studies; however, the deterioration of kidney function in most cases is not serious. Additional attention should be paid to patients treated with cyclophosphamide and carboplatin. Assessment of the early and late effects of the treatment is a key element in improving the quality of the patients' life.
肾母细胞瘤是儿童最常见的肾癌。治疗包括术前和术后化疗、手术,某些情况下还包括放疗。肾母细胞瘤的治疗非常有效。因此,童年时期治愈这种癌症的成年患者群体在稳步增长,由于治疗方法的特殊性和肿瘤的位置,需要对包括肾功能在内的长期健康状况进行评估。
本研究的目的是评估肾母细胞瘤治疗后的肾脏并发症。
研究组由2002年至2012年在波兰弗罗茨瓦夫医科大学儿科血液学、肿瘤学和骨髓移植科接受治疗的50名儿童组成。对患者的病史进行了分析。通过施瓦茨公式估算肾小球滤过率(施瓦茨法估算的肾小球滤过率)、血清肌酐水平、尿素和电解质浓度;评估尿液分析和血压结果。这些分析中的每一项均在诊断时、治疗结束时以及治疗结束后6个月、1年和2年进行。
研究表明,在大多数情况下,实施的治疗对肾母细胞瘤治疗后两年内肾脏参数的恶化没有显著影响。然而,由于肾功能恶化风险较高,接受环磷酰胺和卡铂治疗的患者组需要更仔细的监测。
该研究表明,肾母细胞瘤治疗后肾毒性问题比其他研究表明的更为常见;然而,大多数情况下肾功能的恶化并不严重。应特别关注接受环磷酰胺和卡铂治疗的患者。评估治疗的早期和晚期效果是提高患者生活质量的关键因素。